Compare Stocks: CGEM, TNGX, CDNA, and XENE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDNA CareDx	$70.53 +2.1%	$58.10	$14.23 ▼ $72.71	N/A	N/A	N/A	1.18 million shs
CGEM Cullinan Therapeutics	$14.84 +2.1%	$18.28	$6.73 ▼ $23.19	$935.72M	-0.05	N/A	488,060 shs
TNGX Tango Therapeutics	$22.89 +3.2%	$23.74	$7.37 ▼ $34.39	$3.74B	1.17	N/A	3.32 million shs
XENE Xenon Pharmaceuticals	$36.01 +0.7%	$46.83	$33.38 ▼ $72.66	N/A	N/A	N/A	1.09 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDNA CareDx	+2.07%	+1.92%	+10.76%	+99.18%	+386.08%
CGEM Cullinan Therapeutics	+2.06%	+0.07%	+0.20%	-13.77%	+84.12%
TNGX Tango Therapeutics	+3.15%	-9.35%	-8.15%	-11.45%	+194.59%
XENE Xenon Pharmaceuticals	+0.67%	-0.72%	-2.52%	-42.93%	-14.04%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDNA CareDx	$70.53 +2.1%	$58.10	$14.23 ▼ $72.71	N/A	N/A	N/A	1.18 million shs
CGEM Cullinan Therapeutics	$14.84 +2.1%	$18.28	$6.73 ▼ $23.19	$935.72M	-0.05	N/A	488,060 shs
TNGX Tango Therapeutics	$22.89 +3.2%	$23.74	$7.37 ▼ $34.39	$3.74B	1.17	N/A	3.32 million shs
XENE Xenon Pharmaceuticals	$36.01 +0.7%	$46.83	$33.38 ▼ $72.66	N/A	N/A	N/A	1.09 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDNA CareDx	+2.07%	+1.92%	+10.76%	+99.18%	+386.08%
CGEM Cullinan Therapeutics	+2.06%	+0.07%	+0.20%	-13.77%	+84.12%
TNGX Tango Therapeutics	+3.15%	-9.35%	-8.15%	-11.45%	+194.59%
XENE Xenon Pharmaceuticals	+0.67%	-0.72%	-2.52%	-42.93%	-14.04%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CDNA CareDx	2.38	Hold	$58.40	-17.20% Downside
CGEM Cullinan Therapeutics	2.78	Moderate Buy	$33.71	127.19% Upside
TNGX Tango Therapeutics	2.75	Moderate Buy	$44.62	94.91% Upside
XENE Xenon Pharmaceuticals	2.87	Moderate Buy	$70.14	94.79% Upside

Current Analyst Ratings Breakdown

Latest CGEM, TNGX, CDNA, and XENE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/27/2026	CDNA CareDx	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$74.00 ➝ $81.00
10/23/2026	TNGX Tango Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$55.00
10/19/2026	CDNA CareDx	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$65.00 ➝ $80.00
10/19/2026	CGEM Cullinan Therapeutics	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$40.00
10/16/2026	TNGX Tango Therapeutics	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform
10/8/2026	CDNA CareDx	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C) ➝ Hold (C+)
10/6/2026	XENE Xenon Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$73.00
10/2/2026	CGEM Cullinan Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/2/2026	XENE Xenon Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/2/2026	CDNA CareDx	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Strong-Buy ➝ Hold
10/2/2026	CGEM Cullinan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$35.00

(Data available from 10/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CDNA CareDx	N/A	N/A	N/A	N/A	N/A	N/A
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	$53.81M	71.72	N/A	N/A	N/A	∞
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CDNA CareDx	N/A	$2.07	N/A	111.95	N/A	N/A	N/A	N/A	10/29/2026 (Confirmed)
CGEM Cullinan Therapeutics	N/A	-$3.10	N/A	N/A	N/A	N/A	N/A	N/A	11/5/2026 (Estimated)
TNGX Tango Therapeutics	N/A	-$0.85	N/A	N/A	N/A	N/A	N/A	N/A	11/3/2026 (Estimated)
XENE Xenon Pharmaceuticals	N/A	-$4.74	N/A	N/A	N/A	N/A	N/A	N/A	11/2/2026 (Estimated)

Latest CGEM, TNGX, CDNA, and XENE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	CGEM Cullinan Therapeutics	-$0.8435	N/A	N/A	N/A	$2.00 million	N/A
11/3/2026	Q3 2026	TNGX Tango Therapeutics	-$0.3530	N/A	N/A	N/A	$3.28 million	N/A
11/2/2026	Q3 2026	XENE Xenon Pharmaceuticals	-$1.13	N/A	N/A	N/A	$1.33 million	N/A
10/29/2026	Q3 2026	CDNA CareDx	$0.2548	N/A	N/A	N/A	$121.95 million	N/A
8/11/2026	Q2 2026	TNGX Tango Therapeutics	-$0.3172	-$0.37	-$0.0528	-$0.37	$1.56 million	N/A
8/6/2026	Q2 2026	CGEM Cullinan Therapeutics	-$0.7993	-$0.81	-$0.0107	-$0.81	$3.67 million	N/A
8/6/2026	Q2 2026	XENE Xenon Pharmaceuticals	-$1.16	-$1.11	+$0.05	-$1.11	$1.67 million	N/A
7/30/2026	Q2 2026	CDNA CareDx	$0.2321	$0.37	+$0.1379	$2.07	$114.05 million	$131.95 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CDNA CareDx	N/A	N/A	N/A	N/A	N/A
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CDNA CareDx	N/A
CGEM Cullinan Therapeutics	86.31%
TNGX Tango Therapeutics	78.99%
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
CDNA CareDx	2.40%
CGEM Cullinan Therapeutics	8.60%
TNGX Tango Therapeutics	6.50%
XENE Xenon Pharmaceuticals	2.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CDNA CareDx	765	N/A	50.49 million	Optionable
CGEM Cullinan Therapeutics	109	64.36 million	58.82 million	Optionable
TNGX Tango Therapeutics	137	168.61 million	157.65 million	Optionable
XENE Xenon Pharmaceuticals	364	N/A	93.85 million	Optionable

CGEM, TNGX, CDNA, and XENE Headlines

Recent News About These Companies

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Stock Has Consensus Target Price of $70.14 According to Analysts

3 hours ago | americanbankingnews.com

Xenon Pharmaceuticals (XENE) Expected to Announce Earnings on Monday

October 26 at 4:57 AM | americanbankingnews.com

Xenon Pharmaceuticals (XENE) Set to Post Quarterly Earnings on Monday

October 26 at 4:55 AM | marketbeat.com

Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors

October 20, 2026 | globenewswire.com

Xenon Pharmaceuticals (NASDAQ:XENE) and Beam Therapeutics (NASDAQ:BEAM) Financial Analysis

October 20, 2026 | americanbankingnews.com

XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?

October 15, 2026 | zacks.com

Bank of America Securities Sticks to Their Buy Rating for Xenon (XENE)

October 13, 2026 | theglobeandmail.com

Xenon Pharmaceuticals (NASDAQ:XENE) Hits New 12-Month Low - Here's Why

October 13, 2026 | marketbeat.com

Xenon Pharmaceuticals (NASDAQ:XENE) Cut to "Strong Sell" at Wall Street Zen

October 11, 2026 | marketbeat.com

Why Xenon Pharmaceuticals (XENE) Is Getting Attention Now

October 9, 2026 | finance.yahoo.com

Xenon Pharmaceuticals (XENE) Stock May Still Look Above Fair Value On Its Research Pipeline

October 9, 2026 | uk.finance.yahoo.com

Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors

October 7, 2026 | globenewswire.com

Xenon Pharmaceuticals (NASDAQ:XENE) Sets New 1-Year Low - Here's Why

October 6, 2026 | marketbeat.com

Guggenheim Reaffirms "Buy" Rating for Xenon Pharmaceuticals (NASDAQ:XENE)

October 6, 2026 | marketbeat.com

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 2, 2026

October 5, 2026 | biospace.comB

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Recommendation of "Moderate Buy" from Brokerages

October 3, 2026 | marketbeat.com

Xenon Pharmaceuticals (NASDAQ:XENE) Stock Lifted to "Sell" by Wall Street Zen

October 3, 2026 | marketbeat.com

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 2, 2026 | financialpost.comF

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 2, 2026 | globenewswire.com

Insider Buying: Xenon Pharmaceuticals (NASDAQ:XENE) CFO Buys $559,800.00 in Stock

October 2, 2026 | insidertrades.com

Xenon's AZK Approval Path Unlikely to Be Hurt by Safety Issues, RBC Says

October 1, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEM, TNGX, CDNA, and XENE Company Descriptions

CareDx NASDAQ:CDNA

$70.53 +1.43 (+2.07%)

Closing price 10/27/2026 04:00 PM Eastern

Extended Trading

$70.88 +0.35 (+0.50%)

As of 04:53 AM Eastern

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Cullinan Therapeutics NASDAQ:CGEM

$14.84 +0.30 (+2.06%)

Closing price 10/27/2026 04:00 PM Eastern

Extended Trading

$15.40 +0.56 (+3.76%)

As of 05:25 AM Eastern

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Tango Therapeutics NASDAQ:TNGX

$22.89 +0.70 (+3.15%)

Closing price 10/27/2026 04:00 PM Eastern

Extended Trading

$22.50 -0.39 (-1.68%)

As of 05:01 AM Eastern

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

Xenon Pharmaceuticals NASDAQ:XENE

$36.01 +0.24 (+0.67%)

Closing price 10/27/2026 04:00 PM Eastern

Extended Trading

$36.15 +0.14 (+0.39%)

As of 05:26 AM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CGEM, TNGX, CDNA, and XENE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CGEM, TNGX, CDNA, and XENE Earnings

Compare Dividends

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CGEM, TNGX, CDNA, and XENE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEM, TNGX, CDNA, and XENE Company Descriptions

CareDx NASDAQ:CDNA

Cullinan Therapeutics NASDAQ:CGEM

Tango Therapeutics NASDAQ:TNGX

Xenon Pharmaceuticals NASDAQ:XENE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CGEM, TNGX, CDNA, and XENE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CGEM, TNGX, CDNA, and XENE Earnings

Compare Dividends

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CGEM, TNGX, CDNA, and XENE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEM, TNGX, CDNA, and XENE Company Descriptions

CareDx NASDAQ:CDNA

Cullinan Therapeutics NASDAQ:CGEM

Tango Therapeutics NASDAQ:TNGX

Xenon Pharmaceuticals NASDAQ:XENE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools